Clinical Scorecard: Head-to-Head Trial Compares Iluvien and Anti-VEGF
At a Glance
| Category | Detail |
|---|---|
| Condition | Diabetic Macular Edema (DME) |
| Key Mechanisms | Comparison of Iluvien implant (fluocinolone acetonide 0.19 mg) and anti-VEGF therapy (aflibercept) |
| Target Population | Patients with early diabetic macular edema |
| Care Setting | Clinical trial across multiple centers |
Key Highlights
- Iluvien required less than half the injections compared to aflibercept.
- Similar visual outcomes achieved with Iluvien.
- One-third of Iluvien patients needed no supplemental injections.
- Mean time to first supplemental injection was longer with Iluvien.
- Study followed patients for 18 months.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and retinal imaging for DME diagnosis.
Management
- Consider early use of long-acting corticosteroid implants in DME treatment.
Monitoring & Follow-up
- Regular follow-up for visual outcomes and injection needs.
Risks
- Monitor for potential side effects of corticosteroid implants.
Patient & Prescribing Data
306 eyes enrolled in the NEW DAY trial.
Iluvien group averaged 3.4 injections over 18 months, compared to 7.5 in the aflibercept group.
Clinical Best Practices
- Utilize long-acting corticosteroids for reducing treatment burden.
- Evaluate patient response to initial treatment before supplemental dosing.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.